BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roncato R, Angelini J, Pani A, Cecchin E, Sartore-Bianchi A, Siena S, De Mattia E, Scaglione F, Toffoli G. CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions. Int J Mol Sci 2020;21:E6350. [PMID: 32883002 DOI: 10.3390/ijms21176350] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Sanò MV, Martorana F, Lavenia G, Rossello R, Prestifilippo A, Sava S, Ricciardi GR, Vigneri P. Ribociclib efficacy in special populations and analysis of patient reported outcomes in the MONALEESA trials. Expert Rev Anticancer Ther 2022. [PMID: 35303782 DOI: 10.1080/14737140.2022.2052277] [Reference Citation Analysis]
2 Garutti M, Targato G, Buriolla S, Palmero L, Minisini AM, Puglisi F. CDK4/6 Inhibitors in Melanoma: A Comprehensive Review. Cells 2021;10:1334. [PMID: 34071228 DOI: 10.3390/cells10061334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lukoseviciute M, Maier H, Poulou-Sidiropoulou E, Rosendahl E, Holzhauser S, Dalianis T, Kostopoulou ON. Targeting PI3K, FGFR, CDK4/6 Signaling Pathways Together With Cytostatics and Radiotherapy in Two Medulloblastoma Cell Lines. Front Oncol 2021;11:748657. [PMID: 34631586 DOI: 10.3389/fonc.2021.748657] [Reference Citation Analysis]
4 Nawa H, Niimura T, Yagi K, Goda M, Zamami Y, Ishizawa K. Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments. Cancer Rep (Hoboken) 2021;:e1402. [PMID: 33939324 DOI: 10.1002/cnr2.1402] [Reference Citation Analysis]
5 Garufi G, Carbognin L, Orlandi A, Palazzo A, Tortora G, Bria E. The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature. Front Oncol 2021;11:651723. [PMID: 34692469 DOI: 10.3389/fonc.2021.651723] [Reference Citation Analysis]
6 Masuda N, Chen Y, Kawaguchi T, Dozono K, Toi M. Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels. CMAR 2022;Volume 14:1179-94. [DOI: 10.2147/cmar.s348591] [Reference Citation Analysis]
7 Raschi E, Fusaroli M, Ardizzoni A, Poluzzi E, De Ponti F. Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System. Cancers (Basel) 2021;13:1758. [PMID: 33917020 DOI: 10.3390/cancers13081758] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Roberto M, Astone A, Botticelli A, Carbognin L, Cassano A, D'Auria G, Fabbri A, Fabi A, Gamucci T, Krasniqi E, Minelli M, Orlandi A, Pantano F, Paris I, Pizzuti L, Portarena I, Salesi N, Scagnoli S, Scavina P, Tonini G, Vici P, Marchetti P. CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives. Cancers (Basel) 2021;13:332. [PMID: 33477469 DOI: 10.3390/cancers13020332] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Leenhardt F, Fiteni F, Gauthier L, Alexandre M, Guiu S, Firmin N, Pouderoux S, Viala M, Lossaint G, Gautier C, Mollevi C, Gracia M, Gongora C, Mbatchi L, Evrard A, Jacot W. Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug–Drug Interactions Are the Usual Suspects. Pharmaceutics 2022;14:841. [DOI: 10.3390/pharmaceutics14040841] [Reference Citation Analysis]
10 Elfgen C, Bjelic-Radisic V. Targeted Therapy in HR+ HER2- Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options. Cancers (Basel) 2021;13:5994. [PMID: 34885105 DOI: 10.3390/cancers13235994] [Reference Citation Analysis]
11 Chen YC, Yu J, Metcalfe C, De Bruyn T, Gelzleichter T, Malhi V, Perez-Moreno PD, Wang X. Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer. Expert Opin Investig Drugs 2021;:1-15. [PMID: 34694932 DOI: 10.1080/13543784.2021.1983542] [Reference Citation Analysis]